The LRRC15 protein is representative of a distinct set of TGFβ-driven genes that are predictors of immune checkpoint blockade resistance and unfavorable tumor evolution.4,8 Given LRRC15 known association with TGFβ, immunosuppression, and the observed potential immunomodulatory effects of RIT,27 our second aim was to explore whether the anti-tumor activity induced by [177Lu]Lu-DUNP19 could reverse the signaling profile associated with immunosuppression and resistance to immunotherapy. The gene discussed is LRRC15; the disease is neoplasm.